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G. Coureau et al. / European Journal of Cancer 61 (2016) 146e156 147power and the methodological heterogeneity of European trials question on the possibility of
obtaining valid results separately or by pooling. We conclude, in regard to the lack of strong
scientific evidence, that LDCT screening should not be recommended in subjects highly
exposed to tobacco.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lung cancer is the third most common cancer world-
wide and the first in men for incidence and mortality [1].
Lung cancer is also a major contributor to life lost due
to premature mortality in industrialised countries [2],
and the first cause of cancer death and of lost produc-
tivity due to premature cancer-related mortality [3,4].
Among proven risk factors, cigarette smoking is the
most documented, with almost 90% of lung cancers
potentially attributable to smoking; smoking concerned
nearly a quarter of the world adult population in 2009
[5].
With an overall 5-year survival rate of <20% [6,7],
lung cancer prognosis is poor and varies with the stage
at diagnosis [7e9]. As more than half of lung cancers are
diagnosed at an advanced stage [7,10], earlier detection
would allow treatment at an earlier stage, and could
improve survival. The severity of the disease, the exis-
tence of a pre-clinical phase, the well-defined population
at risk and the existence of treatments most effective in
early stage, make lung cancer potentially suitable for
screening.
Chest X-ray (CXR) screening in subjects highly
exposed to tobacco was never demonstrated to decrease
mortality [11]. The lack of effectiveness might be due to
the poor sensitivity of CXR to detect early stages of
cancer. Based on the hypothesis that low-dose
computed tomography (LDCT) would be more sensi-
tive, randomised controlled trials (RCTs) of lung can-
cer screening with LDCT in subjects at risk were
initiated. Following the first publication of the US
National Lung Screening Trial (NLST) results, sug-
gesting that LDCT screening would be associated with
a decrease in lung cancer mortality [12], two U.S.
groups have recommended this screening be sys-
tematised [13,14]. In France, where no screening is
currently recommended, the National Authority for
Health (HAS), the public body in charge of public
health and practice recommendations, commissioned
our group to carry a systematic review. The objective
was to summarise current scientific evidence, on the
impact of lung cancer screening by LDCT in pop-
ulations highly exposed to tobacco, based on published
randomised trials, with two main questions: what is the
effectiveness? And what are the disadvantages and risks
associated with screening?2. Methods
Three independent experts (G.C., S.M.-P., L.R.S.)
conducted the critical review of the literature, and a
methodological support group (C.E., H.S.-G., C.S.)
validated the protocol, the conduct of the review and
participated in a collegial discussion of the results.
Conclusions were then presented to the HAS. This
report follows the PRISMA guidelines [15].2.1. Search strategy and selection criteria
The literature search was conducted using MEDLINE
and Embase databases. The first search strategy identi-
fied RCTs published in English, between 1st January
2003 and 5th November 2014. Research terms covered
lung cancer, screening and RCTs and their synonyms,
including MeSH terms and terms in titles or abstracts.
This research was completed by: a complementary
Medline search, focussing on the name of trials previ-
ously identified; an interrogation of the clinicaltrial.gov
database; the identification of publications in the refer-
ences of selected articles; and a free-text Internet search
to identify possible publications of protocols. The initial
literature search was updated on 11th March 2015, and
regularly followed for included trials only. Later publi-
cations were not considered as they did not affect the
conclusion of the review.
The four inclusion criteria were: the topic was lung
cancer screening; the design was a RCT; LDCT was
compared to any other intervention; and the study tar-
geted subjects highly exposed to tobacco. All trials
meeting these criteria were included, whenever they
started and whether or not results were available. Re-
views, meta-analyses and trials carried out in subjects
with specific conditions or occupational exposure were
excluded. Publications were independently selected from
the title and abstract list by two authors (G.C., S.M.-P.).
The resulting list was validated during meetings with the
guarantor of this paper (L.R.S.), and discrepancies were
resolved.2.2. Critical appraisal
All publications of a given trial were then assessed by
one member of the independent expert group (G.C.,
G. Coureau et al. / European Journal of Cancer 61 (2016) 146e156148S.M.-P., L.R.S.) who used a form and checklist adapted
from CONSORT [16,17]. This checklist was adapted to
take into account the particularities of effectiveness tri-
als of screening programme. Key elements considered to
provide a full and adequate documentation of the risk-
benefit balance of a screening programme are pre-
sented in Appendix 1.
After the form and checklist were completed, their
contents were revised and discussed with the two other
members of the independent expert group. These ses-
sions allowed clarifying some points, discussing
strengths and limitations of each trial, and drafting
summaries and conclusions. As trials reported results at
different times of follow-up, all results were detailed in
the form, but only the most recent are presented here.
3. Results
3.1. Publications selection and trials’ identification
The first search strategy identified 247 publications of
which 181 (74%) were excluded, (Fig. 1). The 66 publi-
cations selected corresponded to 10 trials for which
focused searches added 17 publications. A total of 83
publications were included for the 10 trials (the list of
references is presented in Appendix 2).Fig. 1. Selection of randomised controlled trials (RCT) assessing the im
(LDCT) in populations highly exposed to tobacco, 11th March 2015.3.2. Trial characteristics and modalities of screening
programme
Two of the ten identified trials were pilot studies, one
had recently started, five were ongoing and two had
published main results (Table 1 and Appendix 2). There
was a large heterogeneity in the compliance with meth-
odological standards, notably regarding the control
arm, study participants, screening protocol, and level of
documentation of informative results regarding the
feasibility, and beneficial and harmful effects of
screening (Tables 1 and 2).
The control arm was annual CXR (DEPISCAN [18],
Lung Screening Study [LSS] [19] and NLST [12,20]),
CXR at inclusion followed by annual clinical examina-
tion (DANTE) [21], annual clinical examination
(Danish Lung Cancer Screening Trial [DLCST] [22])
and ‘usual care’ including smoking cessation pro-
gramme (Nelson [23], Italian Lung study [ITALUNG]
[24], Multicentric Italian Lung Detection study [MILD]
[25], German Lung Cancer Screening Intervention trial
[LUSI] [26], and United Kingdom Lung Cancer
Screening trial [UKLS] [27]). Definition of the included
population varied according to gender (only men for
DANTE and varying among countries for Nelson), age
and smoking history. The latter was mostly based on thepact of lung cancer screening by low-dose computed tomography
Table 1
Description of selected randomised controlled trials assessing the impact of lung cancer screening by low-dose computed tomography in populations highly exposed to tobacco.
Characteristics DEPISCAN LSS NLST NELSON DLCST DANTE ITALUNG MILD LUSI UKLS
Country France USA USA Belgium,
Netherlands
Denmark Italy Italy Italy Germany UK
Period of recruitment 2002e2004 2000 2002e2004 2003eNR 2004e2006 2001e2006 2004e2010 2005e2011 2007e2011 2011e2012
No of centres 14 6 33 4 1 3 3 3 5 2
Intervention in control
arm
CXR CXR CXR Preventiona Yearly clinical
exam
CXR T0b þ yearly
clinical exam
Preventiona Preventiona Preventiona Preventiona
Sample size (subjects) 765 3318 53,454 15,822 4104 2472 3206 4099 4052 NR
No. of screening rounds 2 2 3 4 5 5 4 5 or 3c 5 1
Time between rounds
(years)
1 1 1 1, 1, 2.5d 1 1 1 1 or 2 1 e
Total planned follow-up
(years)
None None 10d NR 10d 5 7 10 NR 10
Availability of mortality
results
Pilot study Pilot study
of NLST
Completede In progress In progress In progress In progress Completede In progress In progress
Expected reduction
of mortality
NR NR 20% at 5 years 25% 25% at 10 years 50% at 5 years NR 30% at
10 years
20% 31% at 5
years
Age (years) 50e75 55e74 55e74 50e69 50e70 60e74 55e69 49 50e69 50e75
Smoking history 15 cig/d  20
years
30 PY 30 PY 15 cig/d  25
years or 10
cig/d  30 years
20 PY 20 PY 20 PY
the last 10
years
20 PY 15 cig/d  25
years or 10
cig/d  30 years
Risk scoref
Maximum time
since smoking
cessation (years)g
15 10 15 10 10 10 10 10 10 None
Gender Both Both Both Menh Both Men Both Both Both Both
Vital status assessment NA NA Questionnaires,
medical records,
National Death
Index
NR National Index,
medical records
Interviews, medical
records, death
registries
Interviews,
medical records
Interviews,
registries, death
certificates
Local registries National index,
medical records,
local registries
Definition of suspicious
nodules (diameter)
>5 mm 4 mm 4 mm Vol 50 mm3
VDT
5 mm 10 mm 5 mm Vol 60 mm3 5 mm þ VDT Vol 50 mm3 or
VDT <400 d
NR, not reported; NA, not applicable; CXR, chest X-ray; PY, pack-years; vol, volume; VDT, volume doubling time.
a Access to a smoking cessation programme.
b Only at the first round (inclusion).
c Five for annual screening group and three for biennial screening group.
d Varies from one article to the other.
e Published, but with a follow-up lower than 10 years.
f Risk score including other factors than smoking history.
g For ex-smokers.
h In the Netherlands, both genders in Belgium.
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Table 2
Main conclusions of critical appraisal of randomised controlled trials assessing the impact of lung cancer screening by low-dose computed to-
mography in populations highly exposed to tobacco.
Items NLST NELSON DLCST DANTE ITALUNG MILD LUSI UKLS
I. Adequacy of methods
Control arm coherent with
recommendations
Partiallya Totallyb Totally Partially Totally Totally Totally Totally
Correct randomisation Totally NR Totally Partially Totally Totally Totally NR
Adequate and long enough
planned follow-up
Partially NR Partially Partially Partially
Measure of all-cause mortality Totally NR Totally NR Totally Totally NR Totally
Measure of specific mortality Totally Totally Totally Totally Totally Totally Totally Totally
Reliable and valid measurement
of mortality
Totally NR Partially Totally Totally Totally Partially NR
Sufficient power and reasonable
effectiveness assumption
Totally Insufficientc Insufficient Insufficient Insufficient Insufficient Insufficient NR
Adequate intent-to-screen analysis Totally NR NR Insufficient NR Totally Insufficient NR
II. Informative results
Correct description of inclusion
and follow-up
[[d [e [ Yf [[ [[ [ NR
Main effectiveness results [ Y Y YYg NR
Measure of observance [[ Y Y NR Y Y Y NR
Measure of contamination [[ [[ [[ [[ NR NR
Adverse effects, false-positives,
false-negatives
Y Y NR NR
Effective dose [[ NR NR NR
Overdiagnosis Y NR NR NR
Smoking cessation [ NR [
Psychological effects Y Y Y
NR, not reported or insufficient for conclusion.
Grey: results not yet available as of 31st December 2015.
a Partially: study partially compliant with methodological standards.
b Totally: study compliant with methodological standards.
c Insufficient: study insufficiently compliant with methodological standards.
d [[: results strongly informative on the feasibility or positive effects of screening.
e [: some informative elements on the feasibility or beneficial effects of screening.
f Y: some informative elements on the lack of feasibility and negative effects of screening.
g YY: clear informative results on the lack of feasibility or harmful effects of screening.
G. Coureau et al. / European Journal of Cancer 61 (2016) 146e156150number of pack-years, but sometimes on the number of
cigarettes and smoking duration, or used a risk score
further including other factors than tobacco.
Screening programme modalities varied between
studies making comparisons difficult. The number of
screening rounds was two to five depending on the
trials, and the follow-up duration was variable and
often too short or unclear. The definition of a positive
test was primarily based on the size of non-calcified
nodules, defined by diameter or volume, but sometimes
on the volume doubling time (VDT). Diagnostic
confirmation often followed a defined approach, but
the treatment strategy was rarely specified and hetero-
geneous between trials or within a same trial (deter-
mined by each participant’s physician). Technical
parameters for imaging were generally well reported in
most trials, but only two reported calculating the mean
effective dose: 1.6 mSv for men and 2.4 mSv for women
in NLST [28], and 6.2 e 6.8 mSv accumulated during
4 years in ITALUNG [29].
The expected difference in mortality between the
intervention and control arms was not alwaysmentioned, and when it was, could be questionable (50%
reduction in mortality at 5 years for DANTE), leading
to an insufficient power for several trials.
3.3. Inclusion, compliance and contamination results
Inclusion rates were not always reported and were
difficult to compare. Study participants represented 27%
of subjects who contacted the study in response to
mailing campaigns and solicitations by physicians in
LSS, 4.5% in ITALUNG (after 23% of response to let-
ters), 1.4% in LUSI (after 33% of response to letters) and
1.6% in UKLS (after 27% of response to letters). Some
trials encountered difficulties in recruiting (MILD),
resulting in limited participation. In DEPISCAN, 120 of
the 765 included subjects (16%) did not meet the inclu-
sion criteria (age, low smoking exposure). In some trials,
the two arms differed significantly regarding smoking
history (DEPISCAN, MILD) or comorbidities
(DANTE). Even without major difficulties, NLST and
DLCST reported differences between the targeted pop-
ulation of subjects at high risk and subjects included:
G. Coureau et al. / European Journal of Cancer 61 (2016) 146e156 151younger age, higher education level and fewer current
smokers than in the source population [30,31]. Among
participants, average participation for all screening
rounds was close to 95% in all trials except in ITA-
LUNG (84%); contamination in the control arm ranged
from 2.3% to 6.1%.
3.4. Mortality results
Among the seven on-going and completed trials, five
published results regarding mortality (Table 3). The
median follow-up duration ranged from 3 to 8 years.
Only one trial (NLST) reported a significant decrease in
specific mortality from lung cancer (risk ratio [RR]
Z 0.84, 95% confidence interval [CI]: 0.75e0.95) and
all-causes mortality (RRZ 0.93, 95% CI: 0.86e0.99)
with LDCT screening compared to CXR screening, after
a median follow-up of 6.5 years [32]. Two trials (DLCST
and MILD) found unfavourable results of screening,
with an increased specific mortalitydalthough not sta-
tistically significantdand a statistically significant
increased all-cause mortality in MILD
(RR5 yearsZ 1.80, 95% CI: 1.03e3.16) [25,33]. For
DLCST, more recent results were published after the
review, with 9.8 years of follow-up, but conclusions were
the same [34] (see comments in Table 3).
3.5. Positive LDCTs and cancer incidence
Based on heterogeneous definitions and confirmation
strategies, the proportion of screened subjects having at
least one positive LDCT ranged from 28% to 46% andTable 3
Most recent mortality results of randomised controlled trials assessing the
(LDCT) in populations highly exposed to tobacco.
NLST DLCST DANT
LDCT Control LDCT Control LDCT
Included sample size 26 722 26 732 2052 2052 1264
Median follow-up (years) 6.5 4.8 8
Lung cancer mortality
Number of deaths
(% included)
469 (1.8) 552 (2.1) 15 (0.7) 11 (0.5) 59 (4.7
Mortality/100,000
person-years
280 332 154a 112a 543
Risk ratio [95%
confidence interval]
0.84 [0.75e0.95] 1.38 [0.63e2.99]a 0.99 [0.
All-cause mortality
Number of deaths
(% included)
1912 (7.2) 2039 (7.6) 61 (3.0) 42 (2.0) 180 (14
Mortality/100,000
person-years
1141 1225 624a 429a 1655
Risk ratio [95%
confidence interval]
0.93 [0.86e0.99] 1.45 [0.98e2.15]a 0.95 [0.
NR, not reported.
For DLCST, results for the most recent publication, in October 2015 (af
screen): 9.8 years; number of lung cancer deaths: 39 versus 38; risk ratioZ
[0.82e1.27].
a Calculated data (for DLCST, follow-up in person-years: 9769 and 9794
b Risk ratio between annual screening and control groups.the proportion of positive results ranged from 9% to
24% of LDCTs done (Table 4). In LUSI, 9% of LDCTs
were positive, based on nodule size and VDT, but
recalculation considering nodule size only brought this
proportion to 29% [35].
In four trials reporting the number of diagnosed lung
cancers, the incidence was greater in the LDCT arm,
with significant risk ratios between 1.13 and 2.88. The
lowest incidence difference was found in NLST
(RRZ 1.13, 95% CI: 1.03e1.23) [32], partly explained
by the longest follow-up period and more cancers in the
control arm during the period after screening.
When information on stage at diagnosis was avail-
able, trials reported a higher proportion of early stage in
the LDCT arm (between 48% and 70% of stage 1) than
in the control arm (between 9% and 31% of stage 1).
This was more noticeable for cancers identified
following a screening test than for interval cancers or
cancers diagnosed during follow-up. Rates of early stage
diagnosis were higher in the LDCT (varying from 12 to
37/1000 screened subjects) than in the control arm in all
studies (from 2 to 14/1000 screened subjects); the reverse
trend was observed for stage 4 diagnosis.
3.6. False-positives
The proportion of false-positives was not frequently
informed and often needed to be recalculated, due to
various denominators used (number of total screened, or
number of screened positive only) (Table 4). False-pos-
itives among LDCTs ranged from 7% to 23%. Among
positive screening LDCTs, 91% e 96% were false-impact of lung cancer screening by low-dose computed tomography
E MILD LUSI
Control LDCT/year LDCT/2 years Control LDCT Control
1186 1190 1186 1723 2029 2023
5 3
) 55 (4.6) 12 (1.0) 6 (0.5) 7 (0.4) NR NR
544 216 109 109 NR NR
69e1.43] 1.98 [0.74e5.28]a,b NR
.2) 176 (14.8) 31 (2.6) 20 (1.7) 20 (1.2) 43 (2.1) 54 (2.7)
1742 558 363 310 NR NR
77e1.17] 1.80 [1.03e3.16]a b NR
ter the end of the selection). Median follow-up (5 years after the last
1.03 [0.66e1.6]; number of deaths: 165 versus 163; risk ratioZ 1.02
).
Table 4
Secondary results of randomised clinical trials assessing the impact of lung cancer screening by low-dose computed tomography (LDCT) in populations highly exposed to tobacco.
NLST DLCST DANTE ITALUNG MILD LUSI
LDCT Control LDCT Control LDCT Control LDCT Control LDCT/year LDCT/2 years Control LDCT Control
Included sample size 26 722 26 732 2052 2052 1264 1186 1613 1593 1190 1186 1723 2029 2023
Median follow-up (years) 6.5 4.8 8 4 5 3
Lung cancer
Number of screening tests done 75,126 73,470 9800 NA NR NA 5333 NA NR NR NA 9160 NA
Number of subjects with at
least one positive screening
over the study period (%)
NR (39.1) NR (16.0) NR NA 359 (28.4) 190 (16.0) 741 (45.9) NA NR NR NA NR NA
Number of positive screenings
(% of screening exam)
18,146 (24.2) 5043 (6.9) 179/2047 (8.7)c NA NR NR 1044 (19.6) NA NR NR NA 805 (8.8)d NA
True positiveZ lung cancera (n) 649 279 68 NA 66 13 38 NA 29 20 NA 58 NA
Interval lung cancerb (n) 71 192 1 NA 15 59 2 NA 5 5 NA 4 NA
Lung cancer during follow-up
after screening or outside
protocol (n)
369 498 0 NA 20 NR NR NA NR NR NA 0 NA
Incidence
Total number of lung cancers (n) 1089 969 69 24 104e 72 40 NR 34 25 20 62 32
Incidence/100,000 person-years 662 588 706f 245f NR NR NR NR 620 457 311 674 363
Risk ratio [95% confidence
interval]
1.13 [1.03e1.23] 2.88 [1.81e4.59]f NR NR 1.99 [1.15e3.46]f,g 1.86 [1.21e2.84]f
Stages
Stage 1 (% of total lung cancers) 50 31 70 25 48 24 64 NR 62 70 NR 69 9
Stage 4 (% of total lung cancers) 22 36 12 54 27 50 13 NR 17 15 NR 8 NR
Stage 1 (/1000 screened subjects) 19.5 10.7 23.4 2.9 37.2 13.5 15.5 NR 11.8 15.2 NR 21.2 1.5
Stage 4 (1000 screened subjects) 8.5 12.5 3.9 6.3 20.6 27.8 3.1 NR 2.5 4.2 NR 2.5 NR
False-positives (n) 17477 4753 302 NA NR NR 1003 NA NR NR NA 747 NA
% of total screenings 23 7 8c NA NR NR 19 NA NR NR NA 8 NA
% of positive tests 96 94 91c NA NR NR 96 NA NR NR NA 93 NA
Surgery (n) 713 239 25c NR 90 31 38 NR 45 NR NR NR NR
% of subjects with positive test 6.8 5.6 14.0 NA 25.0 16.3 5.1 NA NR NR NA NR NA
% of included population 2.7 0.9 1.2 NR 7.1 2.6 2.3 NR 1.9 NR NR NR NR
Surgery procedures for benign
lesion /No of surgery
procedures (%)
186 (26) 48 (20) 8c (32) NR 17 (19) 5 (16) 4 (11) NR 4 (9) NR NR NR NR
NR, not reported; NA, not applicable.
a Screening-detected cancer.
b Lung cancer detected between two rounds.
c Results only for the first round; 179 positive screening.
d Positive screen based on nodule size for T0 and based on the volume doubling time for known nodules for T1eT4; 29.2% if considering only
nodule size >5 mm.
e Including one cancer diagnosed with cytology at T0 and two diagnosed outside the protocol.
f Calculated data.
g Risk ratio comparing annual screening and control groups.
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between 4% and 9%.
3.7. Surgery, complications and quality of life
The frequency of surgical procedures varied between 5%
and 25% of subjects with a positive LDCT examination,
and 1% and 7% of screened subjects (Table 4). Surgery
for lesions eventually rated benign ranged from 9% to
32% of interventions, and was higher in the LDCT than
control arm for the two trials reporting this information
(26% versus 20% for NLST, and 19% versus 16% for
DANTE). Side-effects were partially reported, with
varying denominators and observation periods.
Quality of life was studied only in subsets of partic-
ipants of NLST, DLCST and Nelson [36]. There was no
negative impact of the screening programme for health-
related quality of life, measured by Short Form-36, and
anxiety (State Trait Anxiety Inventory) in NLST [37]
and for stress in Nelson [36]. A negative psychological
impact was observed in both arms after five rounds,
more pronounced in the control arm (DLCST) [38].
3.8. Overdiagnosis and cost-effectiveness
Only two studies considered the excess of diagnoses in
the LDCT arm, although overdiagnosis was not clearly
defined. In DANTE [39], an excess cancer incidence was
not followed by a reduction in mortality, suggesting
overdiagnosis. In NLST [40] however, excess diagnosis
cases being associated with a decrease in mortality could
not correspond to the overdiagnosis definition, as dis-
cussed in methodological articles [41,42].
The cost of the interventions was evaluated in two
trials. In NLST, the cost was estimated at 3074 USD per
person for screening with LDCT, 1911 USD for CXR
screening and 1443 USD in the absence of screening
[43]. The cost-effectiveness ratio of LDCT screening was
valued at 52,000 USD per year of life gained. Further-
more, DLCST reported the cost of screening to prevent
one lung cancer death, based on non-statistically sig-
nificant results on mortality, to more than V177,000
(excluding indirect costs) [44].4. Discussion
We identified ten RCTs planned to evaluate the effec-
tiveness of LDCT screening for lung cancer in heavy
smokers. Three of the trials (LSS and DEPISCAN
feasibility studies, and UKLS pilot study) did not
measure the impact of screening on mortality. Among
the remaining seven, five trials published results on
mortality. Only NLST reported a significant 16%
decrease in disease-specific mortality (with 6.5 years of
median follow-up) and a 7% decrease in all-cause
mortality with LDCT screening when compared toCXR screening. DANTE provided non-significant re-
sults in favour of LDCT screening. Finally, two trials
observed a higher mortality rate in subjects undergoing
LDCT screening (significant for MILD and non-
significant for DLCST). To our knowledge, no other
trial is ongoing, and recent publications of the identi-
fied trials, at the time of submission of this review, do
not affect our main conclusion that the balance be-
tween possible positive and negative effects is insuffi-
ciently documented to recommend screening by LDCT
[34]. Further results are awaited (Nelson, UKLS), but
will probably not bring new elements for reasons dis-
cussed below.
Although many reviews on lung cancer screening
have been published [11,45e48], many results were
published only recently; furthermore, more issues to be
considered before implementing screening at the popu-
lation level were taken into account in our review. We
were thus able to underscore many elements compro-
mising the external validity of these trials and the
reproducibility of results and conclusions. The first
element concerns the difficulty to define the high-risk
population, as documented by the variability in inclu-
sion criteria (history of smoking, risk score) [49].
Recruiting a representative sample [50e52], reaching
minorities and underprivileged populations to avoid
increasing inequalities, is another main challenge. This
issue is critical, not only to define the relevant target
population, but also to estimate the cost-effectiveness of
the screening programme [53,54].
The choice of control arm was inconsistent across
trials. Even though the effectiveness of CXR has not
been proven, one could argue that, in trials using this
control arm, the observed decrease in mortality would
be equal or larger compared with the absence of any
screening. Nevertheless, the use of this control arm
minimises the differences concerning key negative fac-
tors such as false-positives, resulting investigations,
psychological effects and irradiation, as well as mini-
mising the other secondary effects related to LDCT
screening. A recent discussion on cancer screening and
overall mortality advocated a more appropriate control
arm [55].
Defining the content and duration of the screening
programme itself is a major challenge. While the number
of screening rounds and the follow-up have an impor-
tant effect on mortality and on cost-effectiveness, they
differed between trials. For instance, benefits of
screening are short-lived after stopping the programme,
and an initial decrease in mortality will be followed by
an increase [56]. Field et al. [53] emphasised the insuf-
ficient evidence on the adequate LDCT frequency
scheme for screening generalisation and discussed the
strategy of including annual or biennial screens after
2 years of negative LDCTs. Hence, available results are
insufficient to generalise an evidence-based content of
this screening.
G. Coureau et al. / European Journal of Cancer 61 (2016) 146e156154Similarly, defining a positive screen and indetermi-
nate nodules is crucial to evaluate the relevance of a
population-based screening programme. Appropriate
management of screen-detected lung nodules depends
on these definitions. Yet, the different definitions be-
tween trials preclude from comparing the programmes
and reaching conclusions leading to clear recommen-
dations [49]. Some definitions, in particular those based
on volumetric measurement or VDT, are valuable
because they might provide a better value of positive
tests to predict cancer, and thus limit the false-positive
rate and, potentially, overdiagnosis. Nevertheless, they
are rarely fully standardised. A validated risk calculator
that would integrate individual and nodule characteris-
tics is necessary [54].
In this context, the question arises as to the usefulness
of the highly anticipated pooling of data for the Euro-
pean trials. How can pooled results be interpreted for
subjects having been screened a different number of
times and at different rates, as is the case in the Nelson
and DLCST trials [49], point made by the authors
themselves in a recent publication [34]? Moreover, we
confirm the limited statistical power of the European
trials to change the conclusions of NLST, even if the
European trials were combined [34,53,54].
Our review illustrates that many important issues to
consider when comparing trials are not properly
addressed. This may come as a surprise, such a long
time after the first CONSORT statement [57], and
underlines the need to adopt a common language, and
consistent definitions, methods and outcomes in pub-
lications related to screening trials [58]. Necessary in-
formation such as randomisation methods, follow-up
methods or duration of follow-up was often missing or
sometimes contradictory across articles on the same
trial. Furthermore, in most studies, the planned
duration of follow-up after the last round was not
specified.
Many indicators reported in publications could,
under a same name, be related to very different calcu-
lations. This was a difficulty in our work, as some in-
dicators needed to be recalculated. For instance, the
proportion of positive LDCTs could be very different
from one study to another, according to the definition of
a positive screen (LUSI), or denominator (participants
or examinations). The same issue applied to the false-
positive proportion. This further calls for standardised
methods of reporting screening trials [58].
Finally, we believe that most reports of the assessed
RCTs underestimated the importance of identifying
negative effects to adequately judge the effect of sys-
tematic screening. Harms of screening include secondary
effects of false-positive results in the short term, psy-
chological distress, and the effect of repeated irradiation
in the long term, but they were rarely reported and
inconsistent. Indeed, most studies did not specify the
effective dose received, did not consider complementaryexams, and did not evaluate the risk of developing a
radiation-induced cancer in the long term. Over-
diagnosis, another potential disadvantage of screening,
was rarely addressed and used non-standardised calcu-
lation methods [41,42]. The quantification of over-
diagnosis needs to clearly define the ‘evidence of
progression’ in detected nodules [54].
In conclusion, 10 trials, including three pilot studies,
have evaluated LDCT screening for lung cancer. There
is an important variation regarding control arms and
methods employed, which precludes a full comparison
and reproducibility of results. Only one trial has pro-
vided evidence in favour of screening, with a decrease in
disease-specific and all-cause mortality after a 6.5-year
median follow-up. This potential positive effect is
insufficient to recommend screening because no study
provides all elements necessary to document the risk-
benefit balance. In addition, the lack of statistical power
of each European trial and of common methods makes
the possibility of obtaining evidence-based results
separately or by pooled analyses scientifically meaning-
less. Our review highlights issues to be addressed in
screening trials, such as the need to clearly define and
effectively target populations at risk, to develop clear
and validated definitions of positive screen to reduce
false-positives, to harmonise screening modalities and to
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